 This is a Phase 2 study using a traditional Simon two-stage design. Patients 12 years or greater with recurrentrefractory osteosarcoma will be administered avelumab at a dose of 10 mgkg intravenously IV over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. 